Last updated on September 2018

A Study Evaluating ABI-H0731+ NUC vs NUC Alone for the Treatment of Viremic HBeAg-positive CHB Patients


Brief description of study

The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care HBV medication is safe and effective in patients with chronic hepatitis B.

Detailed Study Description

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B

Clinical Study Identifier: NCT03577171

Contact Investigators or Research Sites near you

Start Over

Assembly Biosciences

Infectious Disease Care
Hillsborough, NJ United States
5.74miles
  Connect »